An adolescent with Niemann-Pick disease type C had recurrent catatonia, unsuccessful lorazepam treatment, and improvement during electroconvulsive therapy. A disease-specific case cannot establish the response expected in all catatonia.
Van Verseveld and colleagues described a young patient with recurrent psychiatric and catatonic symptoms whose underlying neurodegenerative lysosomal disorder was identified during the clinical course. Lorazepam did not improve the reported catatonia during initial treatment.
A later episode again involved unsuccessful lorazepam treatment, with paradoxical worsening described by the authors. Electroconvulsive therapy was associated with improvement, while increasing seizure threshold during treatment raised additional clinical questions.
Nonresponse, an adverse behavioral response, and rising ECT seizure threshold are different findings. The report does not experimentally establish a single mechanism connecting them. The authors discuss possible effects of the underlying disease and treatment-related factors.
The case is also selected for its unusual course. It cannot quantify how often patients with Niemann-Pick disease have catatonia, fail benzodiazepines, or develop a particular adverse response.
A failure to improve after a benzodiazepine should not automatically be treated as proof that catatonia was absent. Conversely, escalating treatment does not establish that the original diagnosis was correct. The complete neurological and psychiatric evolution matters.
The report supports attention to underlying disease when treatment resistance and medication intolerance coexist. It does not establish a biomarker, a general contraindication to lorazepam, or an individual causal explanation based only on exposure. Preserve the distinction between a documented unusual response and a population-level rule.
Based on the supplied paper: Case Report Niemann Pick Disease Type C in a Catatonic Patient Treated With Electroconvulsive Therap. PMC8568795.